ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. ShockWave Medical, Inc. was incorporated in 2009 and is headquartered in Santa Clara, California.
IPO Year: 2019
Exchange: NASDAQ
Website: shockwavemedical.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/5/2024 | Outperform → Peer Perform | Wolfe Research | |
| 3/27/2024 | $368.00 | Buy | CL King |
| 9/29/2023 | $218.00 | Neutral | UBS |
| 7/10/2023 | $291.00 → $335.00 | Equal-Weight → Overweight | Morgan Stanley |
| 5/30/2023 | $291.00 | Equal-Weight | Morgan Stanley |
| 3/15/2023 | $240.00 | Buy | Needham |
| 12/16/2022 | $285.00 | Buy | Deutsche Bank |
| 12/12/2022 | $300.00 → $235.00 | Overweight → Equal Weight | Wells Fargo |
| 9/6/2022 | $165.00 | Perform → Underperform | Oppenheimer |
| 4/6/2022 | $255.00 | Outperform | Wolfe Research |